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INTRODUCTION
Proton pump inhibitors (PPIs) are widely and routinely used to treat gastric acid-related disorders, such as gastro-esophageal reflux disease (GERD) and peptic ulcer disease, in both inpatient and outpatient settings. Also, GERD is considered as one of common geriatric diseases, owing to the abnormal peristalsis of the esophagus and dysfunctional 김용광 외: 노인에서 에스오메프라졸과 폐렴 간의 관계 23 production of saliva in the elderly, which in turn makes esophageal mucosa vulnerable to the any damage. Thus, PPIs are more frequently used in the elderly. 1) However, there are considerable debates on the PPIs safety, especially on the long term use of PPIs due to the efficacy and tolerability of them. Some study reported that PPIs have inappropriately prescribed and overused in 50∼60% of the hospitalized patients. 2, 3) Especially, there are numerous studies that have found a significant association between PPIs and pneumonia. [4] [5] [6] [7] [8] [9] [10] One study found that patients who were current users of PPIs (duration ＜30 days or high dose) had a significant association with community-acquired pneumonia (CAP). 8) The association between PPIs and pneumonia has been hypothesized that the increased gastric pH due to the PPI use may facilitate the growth of several bacteria in stomach, where it would be sterile with the normal pH of the stomach. 7) Moreover, this increase in bacteria can lead to pneumonia through microaspiration and lung colonization of them. 11) However, two meta-analyses 12, 13) and another observational study 14) have shown no significant association between PPI use and pneumonia, which, in turn, led to have questions about the link. Recently, Estborn et. al have also found that the occurrence of respiratory tract infections of patients receiving esomeprazole was similar to that of those receiving placebo. 15) Therefore, considering the circumstance that the elderly can be taking many kinds of medication and longer than needed, this study was aimed to analyze this controversial relationship between CAP and PPIs, especially esomeprazole in those who were over 65 years old, with or without Esomeprazole were restricted to oral agents as pneumonia were to community-acquired pneumonia in the outpatient setting. The analysis was done with the important operational definition: pneumonia was limited to the first occurrence after taking esomeprazole over 180 days. Then, the subjects were subdivided according to the duration of esomeprazole treatment as follows: 1 week (reference group for logistic regression), 2 weeks, 3 weeks, 30 days, and more than 31 days. When subdivided, 30 days of interval between administrations was considered a new set point to count.
MATERIALS AND METHODS
The subjects were separated into subgroups according to the gender (female vs. male), and GERD (GERD vs. non-GERD). Also esomeprazole was divided into two groups according to the daily dose; ＜40 mg and ≥40 mg.
Statistical analysis
Mann-Whitney U-test was used to examine the association between the total dose of administrated esomeprazole and the prevalence of pneumonia. Logistic regression was also performed to identify the association between esomeprazole use and pneumonia. (between duration of esomeprazole In subgroup 2 (65≥age; female; GERD), the prevalence 김용광 외: 노인에서 에스오메프라졸과 폐렴 간의 관계 25 In subgroup 2 (65≥age; female; GERD), the prevalence of pneumonia was not significantly associated with esome- and ＜0.001 respectively. Among them, 2 weeks of administration was found to be statistically significant (P=0.006).
In subgroup 4 (65≥age; male; GERD), the prevalence of pneumonia was not significantly associated with esomeprazole use (P=0.682). The OR for 2 weeks, 3 weeks, 30 days, and ≥30 days of administration were 0.798, 1.259, 0.82 and 0.63 respectively and none of them were found to be statistically significant (P=0.479, 0.568, 0.503 and 0.412 respectively).
The association between esomeprazole in total dose and the prevalence of pneumonia
The prevalence of pneumonia was significantly decreased as the total dose of administrated esomeprazole was increased ( Table 3 ). The odds ratio (OR) was 0.998 with 95% Cl (0.997∼0.999) and statistically significant in both Mann-Whitney U-test and logistic regression (P＜0.001 both).
DISCUSSION
Besides of the common adverse effects including headache, nausea, abdominal pain and diarrhea, 16, 17) the use of PPIs has been associated with serval rare adverse effects, such as, vitamin B12 deficiency, [18] [19] [20] [21] [22] iron deficiency. 23, 24) In this study, the association between esomeprazole use and CAP was analyzed by using the National Health Insurance
Service-National Sample Cohort database of Korea from 2007 to 2010.
As shown Table 1 and 2, the subjects were subdivided by the daily dose of esomeprazole (＜40 mg vs. ≥40 mg) and the duration of esomeprazole treatment (1 week, 2 weeks, 3 weeks, 30 days and ≥31 days) over 65 years old.
As a result, the association between the use of esomeprazole and the prevalence of CAP had been failed to have a significant association. The result seemed to be contrary to the above hypothetical mechanism of pneumonia due to PPI use in other studies. However, one population-based case-control study reports that there is not any association between use of PPIs and the increased pneumonia risk and concludes that the observed increased risk in some study may be due to confounding. 14) Jena et al. have also reported that the association between the PPI use and CAP would be confounded and have assessed for that by using the 'falsification approach'. 25) The results of the study showed that similar associations with pneumonia were found in chest pain and urinary tract infection. This suggests that although the PPI use and pneumonia appears to have a significant association statistically, this could be confounded in reality.
In this study, only male patients who took ≥40 mg of esomeprazole daily, were ≥65 years old and did not have GERD showed statistically significant association with pneumonia with high OR of 3 weeks (OR: 4.25; 95% Cl: 1.505∼ 12.004) ( Table 2 ). However, only 3 weeks of duration turned out to be statistically significant while others not.
Thus, without controlling the possible confounding factors, this result can be not interpreted as the meaningful outcome. Moreover, GERD was considered as the confounding factor, but the results showed that GERD was not any sig- Table 3 showed the statistically significant negative association be- Lastly, this study was the first to evaluate the PPIs use and the risk of CAP by using Korean National Sample Cohort database, but to fail to reveal any significant association between the esomeprazole use and the prevalence of pneumonia in the elderly.
